← Leaderboards
Adam Mariusz Bisaga
Columbia University Health Sciences
$21,349,874
Attributed
$32,528,093
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$32,528,093 · 11
By mechanism
UH3$12,060,583 · 1
R01$10,108,089 · 5
UG3$6,825,063 · 1
U01$2,067,142 · 1
K23$667,628 · 1
R21$423,225 · 1
Top collaborators
- Edward V Nunes6 shared
- Sandra D. Comer4 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Edward V Nunes$88,947,598
- Mary Sano$40,764,266
- Frances Rudnick Levin$39,078,718
- Gary K Schwartz$24,362,901
- Wafaa M. El-Sadr$1,113,559,119
Others in their field
Top investigators on “Opioid”
- Chanza Baytop · Westat, Inc.$271,217,917
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Sharon L. Walsh · University Of Kentucky$96,444,120
- Jeffrey H Samet · Boston University Medical Campus$95,014,310
- Edward V Nunes · Columbia University Health Sciences$85,118,880
Research focus
OpioidRelapseNaltrexoneRandomizedPlacebosDoseMethadoneSafetyPharmaceutical PreparationsAgonistParticipantBuprenorphineMaintenanceAbstinenceOpioid WithdrawalBehavioralEffectivenessDisorder Later Incidence PreventionMedicalCravingClinical ResearchDesignBaseOpiate Addiction
Grant awards (35)
Evaluation of safety and pharmacokinetics of naltrexone implant$3,864,542
UH3 · FY2023 · DA · contact PI
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder$686,136
U01 · FY2023 · DA · contact PI
Evaluation of safety and pharmacokinetics of naltrexone implant$4,087,023
UH3 · FY2022 · DA · contact PI
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder$122,647
U01 · FY2022 · DA · contact PI
Evaluation of safety and pharmacokinetics of naltrexone implant$4,109,018
UH3 · FY2021 · DA · contact PI
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder$1,258,359
U01 · FY2020 · DA · contact PI
Evaluation of safety and pharmacokinetics of naltrexone implant$3,713,497
UG3 · FY2019 · DA · contact PI
Evaluation of safety and pharmacokinetics of naltrexone implant$101,428
UG3 · FY2019 · DA · contact PI
Evaluation of safety and pharmacokinetics of naltrexone implant$3,010,138
UG3 · FY2018 · DA · contact PI
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders$192,375
R21 · FY2018 · DA · contact PI
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders$230,850
R21 · FY2017 · DA · contact PI
Improved Strategies for Outpatient Opioid Detoxification$652,661
R01 · FY2015 · DA · contact PI
Training and Education Core$186,760
U54 · FY2015 · DA · contact PI
Improved Strategies for Outpatient Opioid Detoxification$614,979
R01 · FY2014 · DA · contact PI
Training and Education Core$189,603
U54 · FY2014 · DA · contact PI
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$833,527
R01 · FY2013 · DA
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$889,448
R01 · FY2012 · DA
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$877,017
R01 · FY2011 · DA
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$870,800
R01 · FY2010 · DA
Dronabinol naltrexone treatment for opioid dependence$402,500
R01 · FY2010 · DA · contact PI
Memantine Naltrexone Treatment for Opioid Dependence$555,581
R01 · FY2009 · DA · contact PI
Dronabinol naltrexone treatment for opioid dependence$401,042
R01 · FY2009 · DA · contact PI
Memantine Naltrexone Treatment for Opioid Dependence$540,609
R01 · FY2008 · DA · contact PI
Memantine Naltrexone Treatment for Opioid Dependence$536,282
R01 · FY2007 · DA · contact PI
Developing Medication For Tobacco Addiction: NMDA Agents$380,437
R01 · FY2007 · DA · contact PI
Memantine Naltrexone Treatment for Opioid Dependence$539,860
R01 · FY2006 · DA · contact PI
Developing Medication For Tobacco Addiction: NMDA Agents$387,498
R01 · FY2006 · DA · contact PI
Memantine Naltrexone Treatment for Opioid Dependence$510,482
R01 · FY2005 · DA
Developing Medication For Tobacco Addiction: NMDA Agents$392,546
R01 · FY2005 · DA
Developing Medication For Tobacco Addiction: NMDA Agents$388,394
R01 · FY2004 · DA
Developing Medication For Tobacco Addiction: NMDA Agents$334,426
R01 · FY2003 · DA
EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCE$176,666
K23 · FY2003 · DA
EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCE$173,092
K23 · FY2002 · DA
EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCE$161,284
K23 · FY2001 · DA
EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCE$156,586
K23 · FY2000 · DA